Institutional members access full text with Ovid®

Share this article on:

PHOTODYNAMIC THERAPY WITH VERTEPORFIN IN POLYPOIDAL CHOROIDAL VASCULOPATHY: Results After 3 Years of Follow-Up

Leal, Sérgio MD*†; Silva, Rufino MD, PhD*†; Figueira, João MD*†; Cachulo, M Luz MD*†; Pires, Isabel MD*†; de Abreu, José Rui Faria MD, PhD*†; Cunha-Vaz, José Guilherme MD, PhD*†‡

doi: 10.1097/IAE.0b013e3181d37486
Original Article

Purpose: The purpose of this study was to evaluate the efficacy of verteporfin photodynamic therapy on the treatment of polypoidal choroidal vasculopathy.

Methods: A prospective, nonrandomized institutional study was conducted involving 42 eyes of 38 patients with newly diagnosed symptomatic polypoidal choroidal vasculopathy treated exclusively with photodynamic therapy. Twenty-seven eyes completed 3 years of follow-up. Subjects were observed every 3 months with evaluation of best-corrected visual acuity (BCVA), retinography, and fluorescein and indocyanine green angiography. Treatment was given whenever the patient exhibited subfoveal exudation on fluorescein angiography.

Results: Mean BCVA was 0.91 ± 0.33 logarithm of the minimum angle of resolution on the initial visit and 0.93 ± 0.39 on the 36-month visit. Patients were submitted to an average of 3.19 treatment sessions. On the final evaluation at 36 months, 14.8% of the treated eyes improved their BCVA by at least 0.3 logarithm of the minimum angle of resolution, 74.1% had no significant loss of BCVA, and 25.9% lost ≥0.3 logarithm of the minimum angle of resolution. Recurrences were frequent (59.3% of the eyes at 3 years of follow-up), responded well to retreatment, and were not associated with additional BCVA loss.

Conclusion: Photodynamic therapy remains a good option for management of polypoidal choroidal vasculopathy. After 3 years, approximately three fourths of the treated eyes had no significant loss of vision, and 14.8% showed significant improvement in visual acuity.

Photodynamic therapy remains a good option for management of polypoidal choroidal vasculopathy. After 3 years, approximately three fourths of the treated eyes had no significant loss of vision and 14.8% showed significant improvement in visual acuity.

From *the Department of Ophthalmology, University Hospital of Coimbra, Coimbra, Portugal; †the AIBILI-Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal; and ‡the Centre of Ophthalmology, Institute of Biomedical Research on Light and Image, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

The authors have no commercial associations with any of the drugs or companies mentioned on this article.

Reprint requests: Sergio Leal, MD, Department of Ophthalmology, University Hospital of Coimbra, Praceta Mota Pinto, 3004-567 Coimbra, Portugal; e-mail: sergiosilvaleal@gmail.com

© The Ophthalmic Communications Society, Inc.